2Kolb HJ,Mittermüller J,Clemm C,et al.Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients.Blood,1990,76(12):2462-2465. 被引量：1
3Sykes M,Szot GL,Swenson KA,et al.Induction of high levels of allogeneic hematopoietic reconstitution and donorspecific tolerance without myelosuppressive conditioning.Nat Med,1997,3(7):783-787. 被引量：1
4Storb R,Yu C,WagnerJL,et al.Stable mixed hematopoietic chimerism in DLA-identical litterrnate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation.Blood,1997,89(8):3048-3054. 被引量：1
5Niederwieser D,Lange T,Cross M,et al.Reduced intensity conditioning haematopoietic cell transplants in elderly patients with AML.Best Practice and Research Clinical Haematology,2006,19(4):825-838. 被引量：1
6Baron F,Storb R.Hematopoietic cell transplantation after reduced-intensity conditioning for older adults with acute myeloid leukemia in complete remission.Curr Opin Hematol,2007,14(2):145-151. 被引量：1
8Hegenbart U,Niederwieser D,Sandmaier BM,et al.Treatment for acute myelogenous leukemia by low-dose,totalbody,irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors.J Clin Oncol,2006,24(3):444-453. 被引量：1
9de Lima M,Anagnostopoulos A,Munsell M,et al.Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome:dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation.Blood,2004,104(3):865-872. 被引量：1
10van Besien K,Artz A,Smith S,et al.Fludarabine,melphalan,and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome.J Clin Oncol,2005,23(24):5728-5738. 被引量：1
